San Francisco, CA, June 11, 2018 –(PR.com)– Luma Therapeutics, a company dedicated to eradicating suffering from inflammatory skin disease, announces the launch of illuvinateTM, an innovative and modern twist on a safe and effective treatment called the Goeckerman regimen, invented over 100 years ago by a dermatologist at the Mayo Clinic.
Backed by strong clinical trial data, this system enables those suffering from chronic skin conditions such as psoriasis, eczema or vitiligo to experience clear skin after performing therapy in the comfort of their own homes in just minutes a day. By combining a narrowband UVB LED light with patented hydrogels containing coal tar micro-globules, illuvinate increases the skin's hydration, decreases inflammation, and suppresses overactive immune cells.
As a digital therapeutic, the system is controlled by a smartphone app with a doctor’s prescription and Luma’s patented algorithm to modify the dose based on patient feedback. The illuvinate light module attaches magnetically to multi-day wear illuvinate hydrogels, freeing the user to relax during treatment sessions. In addition, users have the ability to share their progress with photographs taken on the app.
Backed by over $6 million in investments from groups such as the Mayo Clinic and Stanford-StartX, illuvinate offers a unique solution for those who don’t want to use messy topicals or pharmaceuticals with potentially harmful side effects. Dr. Jeffrey Sugarman, MD, PhD of Redwood Family Dermatology and UCSF Health expressed his enthusiasm for offering this new technology to his patients. "The illuvinate system was inspired by the Goeckerman regimen and I've been encouraged by the strong clinical data supporting its use in the home for plaque psoriasis. It is easy and convenient to use. It has the potential to help millions of people suffering from psoriasis."
The illuvinate system was created after Evan Anderson, founder and CEO of Luma Therapeutics, tried multiple options for treating his psoriasis. Evan Anderson stated, “I started Luma because I wasn’t happy with available treatments. Clinical trial patients have provided encouraging feedback and we’ve been granted multiple patents for our technology. Now I believe illuvinate is poised to make a meaningful impact on people suffering from inflammatory skin disease.” Currently available for purchase in California, a nationwide launch is planned for early 2019.
Luma Therapeutics is a privately held medical device company committed to developing innovative and convenient light therapies for the millions of people around the world suffering from inflammatory skin disease. Learn more at www.lumatherapeutics.com and www.illuvinate.com.
Anita Greggs Perez
Contact via Email
10 Rollins Road
Millbrae, CA 94030
Read the full story here: https://www.pr.com/press-release/756291
Press Release Distributed by PR.com